Calcium and phosphate metabolism in children with idiopathic hypoparathyroidism or pseudohypoparathyroidism: effects of 1,25-dihydroxyvitamin D3.
Two children with congenital hypoparathyroidism and two children with pseudohypoparathyroidism were given maintenance doses of 15 to 45 ng/kg/day 1,25-dihydroxyvitamin D3 for a total of 255 months. The urinary calcium excretion showed an upward elevation after the first 2 years of treatment but was not significantly higher than that in 10 normal control subjects. The renal threshold for phosphate excretion stayed within the normal ranges compared with control values. Two hypercalcemic and two hypocalcemic episodes occurred during this period of treatment. Hypercalcemia was reversed within 1 week after withdrawal of 1,25-dihydroxyvitamin D3. Hypocalcemia was countered by increasing the dose of 1,25-dihydroxyvitamin D3. Renal functions were not adversely affected, as estimated by creatinine clearance and reciprocals of serum creatinine concentrations. The mean serum calcium concentration during 1,25-dihydroxyvitamin D3 treatment was significantly higher (P = 0.001) compared with that obtained during vitamin D2 treatment at a dose of 500 to 3000 IU/kg/day. These data provide additional support for the long-term use of 1,25-dihydroxyvitamin D3 in idiopathic hypoparathyroidism and pseudohypoparathyroidism.
D002117:Calcitriol / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism* / Q000652:urine; D002648:Child; D003404:Creatinine / Q000378:metabolism; D006128:Growth; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced; D007011:Hypoparathyroidism / Q000151:congenital / Q000188:drug therapy* / Q000378:metabolism; D007223:Infant; D008137:Longitudinal Studies; D010710:Phosphates / Q000378:metabolism* / Q000652:urine; D011547:Pseudohypoparathyroidism / Q000151:congenital / Q000188:drug therapy* / Q000378:metabolism
D010710:Phosphates; D003404:Creatinine; D002117:Calcitriol; D002118:Calcium